Efficacy and Safety of Xacrel® (Ocrelizumab) in Participants With Relapsing Remitting Multiple Sclerosis

NCT04966338 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

170

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Sclerosis
Relapsing-Remitting

Interventions

BIOLOGICAL: Ocrelizumab (CinnaGen, Iran)
BIOLOGICAL: Ocrelizumab (Roche, Switzerland)

Sponsor

Cinnagen